Last 21 quarters of trend data · Healthcare · Medical - Distribution
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
Guardian Pharmacy Services, Inc.'s quarterly P/E stands at 44.8x, up 26.5% year-over-year — indicating the stock has re-rated higher or earnings have softened. EV/EBITDA has expanded 81.3% YoY to 33.5x, reflecting rising market expectations or slowing EBITDA growth.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 54.37 | 44.83 | 22.80 | 43.72 | 38.05 | 35.43 | 25.32 | — | — | — | — | — | — |
| — | +26.5% | -10.0% | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 1.85 | 1.78 | 1.20 | 1.10 | 0.98 | 1.02 | 0.91 | 0.82 | — | — | — | — | — |
| — | +75.4% | +31.6% | +34.9% | — | — | — | — | — | — | — | — | — | |
| P/B Ratio | 12.32 | 10.32 | 8.78 | 8.51 | 7.50 | 8.19 | 8.26 | 7.67 | — | — | — | — | — |
| — | +25.9% | +6.3% | +10.9% | — | — | — | — | — | — | — | — | — | |
| P/FCF | 33.27 | 574.94 | 15.76 | 18.12 | 21.54 | 28.47 | 17.36 | — | — | — | — | — | — |
| — | +1919.4% | -9.3% | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | 23.88 | 33.53 | 8.94 | 17.93 | 18.93 | 18.50 | 14.51 | — | — | — | — | — | — |
| — | +81.3% | -38.4% | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | 29.88 | 33.53 | 12.88 | 24.74 | 26.80 | 25.46 | 19.10 | — | — | — | — | — | — |
| — | +31.7% | -32.6% | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
Guardian Pharmacy Services, Inc.'s operating margin was 5.3% in Q1 2026, down 6.6 pp QoQ and up 1.3 pp YoY. The trailing four-quarter average of 6.3% exceeds the current quarter, suggesting the latest result may reflect seasonal weakness or a one-off headwind. Gross margin expanded 16.0% YoY, indicating pricing power or improving input costs.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 19.5% | 22.7% | 18.8% | 19.8% | 19.8% | 19.5% | 19.8% | 19.4% | 20.4% | 20.0% | 19.4% | 19.9% | 20.6% |
| — | +16.0% | -5.1% | +2.2% | -3.1% | -2.3% | +2.1% | -2.5% | -0.7% | -2.8% | -5.7% | -0.6% | +0.8% | |
| Operating Margin | 6.1% | 5.3% | 11.8% | 4.3% | 3.7% | 3.9% | 4.9% | -33.3% | 5.7% | 2.9% | 5.5% | 10.0% | 2.6% |
| — | +33.0% | +138.7% | +113.0% | -35.5% | +37.1% | -10.4% | -433.4% | +118.5% | -57.5% | -18.6% | +1744.3% | -66.6% | |
| Net Margin | 3.4% | 3.9% | 5.3% | 2.6% | 2.6% | 2.9% | 3.5% | -35.8% | 3.5% | 1.0% | 4.3% | 8.5% | 0.7% |
| — | +37.7% | +49.2% | +107.3% | -25.9% | +183.6% | -17.5% | -522.9% | +417.3% | -79.5% | -13.4% | +461.8% | -88.6% |
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 26.8% | 5.9% | 10.1% | 5.2% | 5.3% | 6.0% | 8.4% | -117.9% | 18.1% | 4.7% | 17.6% | 28.7% | 2.3% |
| — | -2.1% | +20.3% | +104.4% | -71.0% | +29.6% | -52.2% | -510.4% | +691.6% | -69.8% | -2.8% | +425.1% | -88.8% | |
| ROA | 13.4% | 3.2% | 5.2% | 2.6% | 2.6% | 2.9% | 3.6% | -34.5% | 3.5% | — | 4.5% | 8.1% | 0.7% |
| — | +9.7% | +46.0% | +107.6% | -24.9% | — | -20.3% | -523.5% | +429.3% | — | -5.8% | +485.8% | -88.1% | |
| ROIC | 35.8% | 6.7% | 18.4% | 6.2% | 5.0% | 5.4% | 7.1% | -51.7% | 13.3% | 6.3% | 8.6% | 14.0% | 3.6% |
| — | +24.3% | +159.6% | +112.0% | -62.5% | -14.4% | -17.8% | -469.6% | +268.1% | -27.4% | -17.1% | +1576.8% | -65.7% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
Guardian Pharmacy Services, Inc.'s Debt/EBITDA ratio is 2.1x, up from 0.7x last quarter — at a moderate level that warrants monitoring. The current ratio has improved 28.2% YoY to 1.46x, strengthening the short-term liquidity position. Debt/Equity has declined for 4 consecutive quarters, reflecting a deleveraging trend.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.17 | 0.16 | 0.17 | 0.17 | 0.22 | 0.17 | 0.25 | 0.56 | 1.33 | — | 1.16 | 0.85 | 0.79 |
| — | -9.0% | -31.5% | -68.8% | -83.3% | — | -78.5% | -34.5% | +68.7% | — | +39.3% | -17.3% | -23.9% | |
| Debt / EBITDA | 0.33 | 2.09 | 0.70 | 1.47 | 2.21 | 1.56 | 1.70 | — | 4.49 | — | 3.42 | 2.21 | 5.25 |
| — | +34.0% | -58.7% | — | -50.9% | — | -50.1% | — | -14.3% | — | +10.2% | -88.6% | +62.0% | |
| Current Ratio | 1.38 | 1.46 | 1.38 | 1.22 | 1.18 | 1.14 | 1.05 | 1.14 | 0.90 | — | 0.94 | 1.01 | 1.09 |
| — | +28.2% | +30.8% | +7.5% | +31.2% | — | +12.3% | +12.9% | -17.3% | — | -12.3% | +0.5% | +13.4% | |
| Quick Ratio | 1.11 | 1.17 | 1.11 | 0.93 | 0.88 | 0.84 | 0.77 | 0.85 | 0.66 | — | 0.67 | 0.73 | 0.76 |
| — | +38.8% | +43.5% | +8.9% | +32.7% | — | +14.9% | +16.8% | -13.2% | — | -4.0% | +3.4% | +16.5% | |
| Interest Coverage | 133.71 | 114.77 | 224.52 | 104.94 | 74.18 | 78.09 | 39.53 | -101.96 | 15.87 | 10.27 | 20.70 | 35.82 | 9.14 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 21 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying GRDN stock.
Guardian Pharmacy Services, Inc.'s current P/E is 54.4x. The average P/E over the last 4 quarters is 37.3x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Guardian Pharmacy Services, Inc.'s current operating margin is 6.1%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Guardian Pharmacy Services, Inc.'s business trajectory between earnings reports.